Sara Eichau

Efficacy and Safety of Alemtuzumab Through 9 Years of Follow-up in Patients with Highly Active Disease: Post Hoc Analysis of CARE-MS I and II Patients in the TOPAZ Extension Study

Tjalf Ziemssen, Ann Bass, Regina Berkovich et al. · CNS Drugs · 2020 · 56 citations · Full text

Medicine, Neurology, Pharmacotherapy +17

Association of Serum Neurofilament Light Chain Levels at Disease Onset With Disability Worsening in Patients With a First Demyelinating Multiple Sclerosis Event Not Treated With High-Efficacy Drugs

Enric Monreal, José Ignacio Fernández-Velasco, María Isabel García-Sánchez et al. · JAMA Neurology · 2023 · 47 citations · Full text

Life Sciences, Neurology, Neuroscience +15

Serum biomarkers at disease onset for personalized therapy in multiple sclerosis

Enric Monreal, José Ignacio Fernández-Velasco, Roberto Álvarez‐Lafuente et al. · Brain · 2024 · 39 citations · Full text

Life Sciences, Biostatistics, Neurology +15

Identification of Patients With Relapsing Multiple Sclerosis Eligible for high-efficacy Therapies

José Meca-Lallana, J.A. García-Merino, Sergio Martínez‐Yélamos et al. · Neurodegenerative Disease Management · 2021 · 12 citations

Medicine, Neurology, Clinical Decision Support +14

Consensus on early detection of disease progression in patients with multiple sclerosis

José Meca-Lallana, Bonaventura Casanova, Alfredo Rodríguez-Antigüedad et al. · Frontiers in Neurology · 2022 · 12 citations · Full text

Life Sciences, Neurology, Neuroscience +12